A Phase 1 Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 15 Aug 2019 Planned End Date changed from 30 Dec 2020 to 31 Mar 2022.
- 30 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.